Acadia, deCODE: Venture Bets On Comeback Kids Pay Off
This article was originally published in Start Up
Executive Summary
Two long-in-the-tooth biotechs, Acadia and deCODE, were desperate for help. The venture investors who helped bail them out have seen their investments pay off nicely. Promising Phase III data for its lead compound have boosted Acadia’s stock, and Amgen spent generously to buy deCODE’s genetic expertise for its own drug discovery efforts.
You may also be interested in...
deCODE Re-Emerges: Can a Genomics Platform Model Work in Diagnostics?
deCODE Genetics has emerged from bankruptcy with a streamlined, diagnostics-oriented business model. In the near term, the privately held firm expects to offer its genomics discovery capabilities on a service basis, echoing the original genomics platform specialists of the late 1990s, including deCODE itself, which did largely unsuccessful technology deals focused on using genetic insight to generate therapies. The difference? It is now using genetic information to assess disease risk and better manage patient health, a strategy it thinks will succeed as the field of personalized medicine diagnostics continues to gain traction.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.